Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

93 Percent of Nucleoside-Naive Chronic Hepatitis B e-Antigen (HBeAg)-Negative Patients Achieved Undetectable Viral Load by Week 48 of Re-Treatment

PRINCETON, N.J., April 13, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced data from a cohort of nucleoside-naive HBeAg-negative chronic hepatitis B patients (ETV-027/901, n=99). These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption of treatment with BARACLUDE(R) (entecavir) achieved viral suppression and liver enzyme (ALT) normalization when re- treated for 48 weeks with BARACLUDE. The study results were presented at the 42nd Annual Meeting of the European Association for the Study of Liver Diseases (EASL) in Barcelona, Spain.

In this cohort, 93 percent of patients who were re-treated with BARACLUDE had undetectable viral load - the level of the hepatitis B virus in the blood - (HBV DNA <300 copies/mL, measured by a common assay - polymerase chain reaction or PCR) and 83 percent achieved liver enzyme normalization (ALT less than or equal to 1xULN) after 48 weeks of therapy.

"This study showed that when treated again with BARACLUDE for 48 weeks, patients achieved responses similar to those seen prior to treatment interruption, with safety results consistent with previously reported experience," said Hakan Senturk, MD, of the Ist.Univ.Cerrahpasa Tip Fak, Istanbul, Turkey.

No deaths or treatment discontinuations due to adverse events were reported in this cohort. The most common adverse events occurring in greater than 10 percent of patients were abdominal pain, fatigue, upper respiratory tract infection, nasopharyngitis, increased ALT, arthralgia, and headache.

About the Nucleoside-Naive HBeAg-Negative BARACLUDE(R) (entecavir) Re- Treatment Cohort

This analysis evaluated BARACLUDE(R) (entecavir) in nucleoside-naive chronic HBeAg-negative patie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:7/24/2014)... Sciences, Inc. (NASDAQ: ALIM ) ("Alimera"), a ... commercialization of prescription ophthalmic pharmaceuticals, today announced that it ... financial results after the market close on Thursday, August ... the same day at 4:30 p.m. ET. ... Dan Myers , President and Chief Executive Officer, and ...
(Date:7/24/2014)... RALEIGH-DURHAM, N.C. , July 24, 2014 /PRNewswire/ ... company has signed an Agreement with Kineticos, a ... sciences consulting company. Kineticos will support LSI Medience ... in sepsis management, to demonstrate utility in clinical ... has shown potential utility in diagnosis of sepsis, ...
(Date:7/24/2014)... -- Perrigo Company (NYSE: PRGO ; TASE) today ... rating from the U.S. Food and Drug Administration (FDA) ... testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone product ... be substituted with the full expectation that it will ... AndroGel 1% when used under the conditions specified in ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
(Date:7/24/2014)... Newark, NJ (PRWEB) July 24, 2014 ... which will give one lucky family a rent-free week ... only until August 3, 2014. Don’t miss your chance ... The sweepstakes is open to all New Jersey residents, ... Horizon BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , ...
(Date:7/24/2014)... Memantine was initially developed by Merz to treat ... the brand name Akatinol; it was later licensed to Lundbeck ... the USA to Forest Labs as Namenda. Lundbeck reported the ... the US, Forest reported Namenda sales of USD 1.5 billion ... and the European region has increased the competition from generic ...
(Date:7/24/2014)... In signing the Workforce Innovation and ... Atlanta BeltLine Workforce Partnership in Healthcare as one ... ( http://www.whitehouse.gov/ready-to-work ). The Administration called for ... economic strategy and profiled successful local efforts to ... Obama highlights the power of partnerships in Atlanta,” ...
(Date:7/24/2014)... July 24, 2014 As the age ... to egg freezing as a way to ensure future ... otherwise decline with advancing reproductive age. Vitrification technology, a ... cutting edge medical technology that allows a woman to ... peak fertility years, which are then stored for future ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Members of the ... Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, as ... appointed him to the Board and that his peers chose ... want to provide the best I can for the citizens ... am uniquely positioned to provide a special insight to concerns ...
Breaking Medicine News(10 mins):Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... radiation retinopathy who were destined to go blind within ... localized treatment with Avastin , a well-known cancer drug, ... 2007 Archives of Ophthalmology. ,This is a major ... radiation therapy and commonly develop radiation retinopathy, said Paul ...
... potentially lethal H5N1 strain of bird flu was confirmed this ... ,"All the turkeys on the farm have been killed and ... area, around 1,000 birds in all," Czech veterinary services spokesman ... (Friday)," he added. ,The H5N1 strain of bird flu ...
... people in Vietnam in the first six months of the ... period last year, the health ministry said Friday. ... 15 percent rise to 19,144 new infections from the mosquito-borne ... delta. ,Malaysia and other Southeast Asian countries have ...
... Researchers have formed a new compound AN2690, that might ... blocking an enzyme crucial for the protein synthesis of ... a team of researchers including Dickon Alley and Stephen ... Molecular Biology Laboratory (EMBL) outstation in Grenoble, France. ...
... an Anglo-American company has been allowed to store white ... by the US Food and Drug Administration. ... immune system that defend the body against both infectious ... take 480-millilitre of blood from interested healthy individuals and ...
... welcomed the European Union (EU) Parliament's resolution to ban mercury ... to do likewise. ,Toxics Link and other ... ,The group had called upon governments across the world to ... Programme (UNEP) in February. ,In one of ...
Cached Medicine News:Health News:Untreatable Eye Disease Improves With Avastin 2Health News:Researchers Devise New Compound to Treat Fungal Infections 2
... to enhance the chin contour, this chin implant ... high-profile central chin projection. Symmetrical Chin Implants ... implant provides a high central projection, as well ... Chin Implants - Designed with a unique shape, ...
... Speed and simplicity at the point of ... result , Sample volume of only 70 L of ... ~ 20 minutes after change of sensor cassette , ... to sample (mixes a sample in 7 seconds) ...
... IEC CL40 and FL40 Centrifuge Series ... and versatility to increase your productivity ... broad array of rotors and accessories ... microplate applications, the IEC CL40 and ...
... The IEC CL30 Series ... and exceptional value for your ... unique AUTO-LOCK rotor exchange system, ... capacity, the IEC CL30 Series ...
Medicine Products: